229 related articles for article (PubMed ID: 33317068)
21. Understanding the Hsp90
Magwenyane AM; Mhlongo NN; Lawal MM; Amoako DG; Somboro AM; Sosibo SC; Shunmugam L; Khan RB; Kumalo HM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32295059
[TBL] [Abstract][Full Text] [Related]
22. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
23. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
[TBL] [Abstract][Full Text] [Related]
24. Complex crystal structure determination and anti-non-small-cell lung cancer activity of the Hsp90
Qin W; Yu F; Zhou H; Li P; Zhou F; Li HJ; He CX; Xing L; Zhou X; Zhao D; Li PQ; Jin X; Wang QS; He JH; Cao HL
Acta Crystallogr D Struct Biol; 2021 Jan; 77(Pt 1):86-97. PubMed ID: 33404528
[TBL] [Abstract][Full Text] [Related]
25. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.
Lee JH; Shin SC; Seo SH; Seo YH; Jeong N; Kim CW; Kim EE; Keum G
Bioorg Med Chem Lett; 2017 Jan; 27(2):237-241. PubMed ID: 27914802
[TBL] [Abstract][Full Text] [Related]
27. Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.
Yoshimura C; Nagatoishi S; Kuroda D; Kodama Y; Uno T; Kitade M; Chong-Takata K; Oshiumi H; Muraoka H; Yamashita S; Kawai Y; Ohkubo S; Tsumoto K
J Med Chem; 2021 Mar; 64(5):2669-2677. PubMed ID: 33621080
[TBL] [Abstract][Full Text] [Related]
28. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
He W; Hu H
Oncol Rep; 2018 Jul; 40(1):3-15. PubMed ID: 29749536
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
[TBL] [Abstract][Full Text] [Related]
30. Anti-NSCLC activity in vitro of Hsp90
Li HJ; Wang QS; Han W; Zhou H; Li P; Zhou F; Qin W; Zhao D; Zhou X; He CX; Xing L; Li PQ; Jin X; Yu F; He JH; Cao HL
J Struct Biol; 2021 Jun; 213(2):107710. PubMed ID: 33610655
[TBL] [Abstract][Full Text] [Related]
31. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
Sharp SY; Prodromou C; Boxall K; Powers MV; Holmes JL; Box G; Matthews TP; Cheung KM; Kalusa A; James K; Hayes A; Hardcastle A; Dymock B; Brough PA; Barril X; Cansfield JE; Wright L; Surgenor A; Foloppe N; Hubbard RE; Aherne W; Pearl L; Jones K; McDonald E; Raynaud F; Eccles S; Drysdale M; Workman P
Mol Cancer Ther; 2007 Apr; 6(4):1198-211. PubMed ID: 17431102
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
Sun J; Lin C; Qin X; Dong X; Tu Z; Tang F; Chen C; Zhang J
Bioorg Med Chem Lett; 2015 Aug; 25(16):3129-34. PubMed ID: 26112442
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
[TBL] [Abstract][Full Text] [Related]
35. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
Shen G; Wang M; Welch TR; Blagg BS
J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
38. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
Patel HJ; Patel PD; Ochiana SO; Yan P; Sun W; Patel MR; Shah SK; Tramentozzi E; Brooks J; Bolaender A; Shrestha L; Stephani R; Finotti P; Leifer C; Li Z; Gewirth DT; Taldone T; Chiosis G
J Med Chem; 2015 May; 58(9):3922-43. PubMed ID: 25901531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
